Akari Therapeutics PLC (NASDAQ:AKTX) has received an average broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company. Akari Therapeutics PLC’s rating score has improved by 33.3% in the last three months as a result of various analysts’ ratings changes.

Analysts have set a one year consensus price target of $2.50 for the company and are anticipating that the company will post ($1.00) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Akari Therapeutics PLC an industry rank of 115 out of 265 based on the ratings given to related companies.

Several research firms have recently weighed in on AKTX. Zacks Investment Research downgraded shares of Akari Therapeutics PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 price target on shares of Akari Therapeutics PLC in a research note on Friday, September 22nd. William Blair raised shares of Akari Therapeutics PLC from a “market perform” rating to an “outperform” rating in a research note on Friday, September 22nd. Chardan Capital reaffirmed a “neutral” rating on shares of Akari Therapeutics PLC in a research note on Sunday, September 17th. Finally, ValuEngine raised shares of Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research note on Monday, September 11th.

ILLEGAL ACTIVITY NOTICE: “Akari Therapeutics PLC (AKTX) Given Average Rating of “Buy” by Analysts” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/13/akari-therapeutics-plc-aktx-given-average-rating-of-buy-by-analysts.html.

An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Hikari Power Ltd acquired a new stake in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned about 0.51% of Akari Therapeutics PLC at the end of the most recent reporting period. 26.97% of the stock is currently owned by institutional investors and hedge funds.

Akari Therapeutics PLC (AKTX) traded up $0.23 during trading on Monday, hitting $4.48. 133,200 shares of the stock traded hands, compared to its average volume of 385,001. Akari Therapeutics PLC has a 1 year low of $3.18 and a 1 year high of $22.20.

Akari Therapeutics PLC Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Get a free copy of the Zacks research report on Akari Therapeutics PLC (AKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related stocks with our FREE daily email newsletter.